Department of Urology, Assaf Harofeh Medical Center, Zerifin, Israel.
Urology. 2010 Feb;75(2):277-80. doi: 10.1016/j.urology.2009.06.110. Epub 2009 Nov 6.
To define the rate of positive surgical margins (PSMs) and analyze the outcome of patients with PSMs. The outcome and proper management of patients with positive PSMs during nephron sparing surgery (NSS) are questionable. In this study we define the clinical outcomes of PSMs at NSS and suggest management.
Clinical records of 114 renal units who underwent open NSS for a renal mass between May 1995 and September 2005 were reviewed.
PSMs were suspected on frozen section in 17 of 114 renal units (15%). Tumors with suspected PSMs at frozen section were smaller (2.9 +/- 1.6) in comparison to those with negative surgical margins (3.4 +/- 1.8 cm) (P = .001). Nine of 17 (53%) cases underwent total nephrectomy (5 immediately, 4 delayed). In 4 (24%), immediate re-excision of the renal crater was performed. A total of 4 (24%) that were followed up clinically were with no evidence of disease. Therefore, in 13 of 17 (77%) cases, the presence of tumor cells at the remaining side of the kidney could be evaluated histologically. In 2 cases from the immediate response group, tumor cells were found in the side opposite to the resection. There was no residual tumor in any case subjected to delayed nephrectomy. At median follow-up of 71 months, 15 of 17 patients are alive and with no evidence of disease. Two patients died because of unrelated causes. The overall 5-year survival rate is 98.2% and there is no cancer-specific mortality.
The true PSM rate is in the range of 1.75%-5.26%. No disease progression or deaths attributable to renal cell carcinoma were associated with PSMs. Total nephrectomy should be avoided as a response to PSMs.
定义阳性手术切缘(PSM)的发生率,并分析 PSM 患者的预后。保肾手术(NSS)中 PSM 患者的预后和适当的处理方法仍存在争议。本研究旨在定义 NSS 中 PSM 的临床结局,并提出相应的处理建议。
回顾性分析 1995 年 5 月至 2005 年 9 月期间 114 例接受开放 NSS 治疗的肾脏肿块患者的临床资料。
114 例肾脏中,有 17 例(15%)在冰冻切片时怀疑存在 PSM。与阴性手术切缘相比,冰冻切片怀疑 PSM 的肿瘤较小(2.9+/-1.6 比 3.4+/-1.8cm,P=0.001)。17 例中 9 例(53%)行根治性肾切除术(5 例即刻,4 例延迟)。其中 4 例(24%)行肾切除残端即刻再次切除术。4 例(24%)患者接受临床随访,无疾病证据。因此,在 17 例中有 13 例(77%)可对肿瘤细胞在肾脏剩余侧的情况进行组织学评估。在即刻反应组的 2 例中,在对侧发现肿瘤细胞。延迟性肾切除的所有病例均未见残留肿瘤。在中位随访 71 个月时,17 例患者中有 15 例存活且无疾病证据。2 例患者因非相关原因死亡。总的 5 年生存率为 98.2%,无肿瘤特异性死亡率。
真正的 PSM 发生率为 1.75%-5.26%。PSM 与肿瘤进展或肾细胞癌相关的死亡无关。PSM 不应作为行根治性肾切除术的指征。